Lutetium-177 Supply Global Market Report 2026

Lutetium-177 supply refers to the production, processing, and distribution of the radioactive isotope Lutetium-177 used in targeted radionuclide therapy and nuclear medicine applications. It is produced through nuclear reactor- or cyclotron-based methods and is intended to deliver localized radiation for therapeutic procedures while supporting precision treatment approaches. It requires specialized handling, quality assurance, packaging, and transportation infrastructure to ensure safety, stability, and regulatory compliance.

The primary production methods of lutetium-177 supply include reactor-produced lutetium-177, cyclotron-produced lutetium-177, carrier-added lutetium-177, and non-carrier-added lutetium-177. Reactor-produced lutetium-177 refers to a medical radioisotope used in targeted radionuclide therapy, particularly for oncology applications. These supplies are distributed through direct supply agreements, radiopharmaceutical distributors, hospital procurement channels, and research supply networks. The key applications include neuroendocrine tumor treatment, prostate cancer treatment, bone metastasis treatment, clinical research applications, and others, while the end-users include hospitals, specialty cancer clinics, research institutes, radiopharmaceutical companies, and diagnostic centers.

Tariffs are influencing the lutetium-177 supply market by increasing the cost of imported reactor components, cyclotron systems, isotope processing equipment, shielding materials, and specialized transportation infrastructure required for radioisotope production and distribution. This is creating cost pressures across reactor-produced lutetium-177, cyclotron-produced lutetium-177, and non-carrier-added lutetium-177 segments, particularly in regions dependent on imported nuclear medicine technologies such as Asia-Pacific and parts of Europe. Hospitals, specialty cancer clinics, radiopharmaceutical companies, and research institutes are experiencing higher procurement and operational expenses due to global supply chain disruptions. However, tariffs are also encouraging domestic isotope production investments, regional supply chain development, and local manufacturing of critical nuclear medicine infrastructure, supporting long-term supply security and market resilience.

The lutetium-177 supply market size has grown rapidly in recent years. It will grow from $1.4 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to rising prevalence of cancer indications requiring targeted radionuclide therapy, increasing clinical adoption of radiopharmaceutical treatments, expansion of nuclear medicine infrastructure globally, growing investments in medical isotope production facilities, increasing regulatory approvals for lutetium-177 based therapies.

The lutetium-177 supply market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, increasing expansion of commercial radiopharmaceutical manufacturing capacity, rising investments in advanced isotope production technologies, increasing development of novel lutetium-177 therapeutic applications, growing establishment of regional isotope supply networks. Major trends in the forecast period include increasing expansion of reactor based isotope production capacity, growing focus on high purity lutetium-177 supply chains, rising investments in radiopharmaceutical logistics infrastructure, increasing adoption of non carrier added lutetium-177 production methods, growing emphasis on regulatory compliant isotope transportation networks.

The rising prevalence of cancer is expected to propel the growth of the lutetium-177 supply market going forward. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The prevalence of cancer is increasing due to the aging population, as older age remains one of the most significant risk factors for the development of most cancer types, with a large proportion of cases occurring in individuals aged 65 years and above. Lutetium-177 supply supports targeted cancer therapies by delivering precise radiation directly to tumor cells while minimizing damage to healthy tissues, improving treatment outcomes for neuroendocrine tumors and metastatic prostate cancer and advancing personalized oncology care globally. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase from the estimated 20 million cases reported in 2022. Therefore, the rising prevalence of cancer is driving the growth of the lutetium-177 supply market.

Major companies operating in the lutetium-177 supply market are focusing on developing advanced initiatives, such as large-scale commercial radioisotope production platforms, to improve the availability, reliability, and scalability of medical isotopes used in targeted cancer therapies and diagnostic imaging applications. Large-scale commercial radioisotope production platforms are sophisticated manufacturing systems designed to generate medical isotopes in high volumes through scalable irradiation and purification processes, ensuring a stable, dependable, and continuous supply of therapeutic and diagnostic isotopes for cancer treatment and nuclear medicine applications. For instance, in January 2025, Nusano Inc., a US-based radioisotope development company, launched commercial isotope operations and announced a lutetium-177 supply agreement with GlyTherix. This initiative supports the production and distribution of Lu-177 for targeted radiopharmaceutical therapies while also providing future access to isotopes such as actinium-225, zirconium-89, lead-212, and terbium-161. Nusano's flagship facility in West Valley City, Utah, is designed to simultaneously produce up to 12 different radioisotopes and ultimately support a portfolio of more than 25 isotopes for life sciences applications. The platform strengthens isotope supply reliability for clinical trials and commercial therapeutic programs, particularly for oncology-focused radiopharmaceuticals that target aggressive cancers through precision molecular therapies.

In July 2023, ITM Isotope Technologies Munich SE, a Germany-based radiopharmaceutical biotechnology company specializing in the manufacturing of non-carrier-added Lutetium-177, partnered with POINT Biopharma Global Inc. to expand their global supply agreement for non-carrier-added Lutetium-177 (n.c.a. ^177Lu). Through this partnership, ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. aim to support the clinical and potential future commercial development of ^177Lu-based radiopharmaceuticals across POINT's oncology pipeline by ensuring a scalable and dependable supply of high-purity medical radioisotopes. POINT Biopharma Global Inc. is a US-based radiopharmaceutical company engaged in the discovery, development, and commercialization of targeted radioligand therapies for cancer treatment.

Major companies operating in the lutetium-177 supply market are Novartis AG; Telix Pharmaceuticals Limited; Bayer AG; Cardinal Health Inc.; Siemens Healthineers AG; Curium International Trading B.V.; Eckert & Ziegler SE; NRG PALLAS B.V.; State Atomic Energy Corporation Rosatom; Framatome SAS; BWX Technologies Inc.; National Centre for Nuclear Research Radioisotope Centre POLATOM; Isotopia Molecular Imaging Ltd.; Nusano Inc.; ITM Isotope Technologies Munich SE

North America was the largest region in the lutetium-177 supply market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lutetium-177 supply market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lutetium-177 supply market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lutetium-177 supply market consists of sales of radiopharmaceutical isotopes, radioactive source materials, isotope processing equipment, shielding containers, and related nuclear medicine products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The lutetium-177 supply market research report is one of a series of new reports from The Business Research Company that provides lutetium-177 supply market statistics, including lutetium-177 supply industry global market size, regional shares, competitors with a lutetium-177 supply market share, detailed lutetium-177 supply market segments, market trends and opportunities, and any further data you may need to thrive in the lutetium-177 supply industry. This lutetium-177 supply market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lutetium-177 Supply Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses lutetium-177 supply market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lutetium-177 supply ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lutetium-177 supply market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Production Method: Reactor Produced Lutetium One Hundred Seventy-Seven; Cyclotron Produced Lutetium One Hundred Seventy-Seven; Carrier Added Lutetium One Hundred Seventy-Seven; Non Carrier Added Lutetium One Hundred Seventy-Seven
• 2) By Distribution Channel: Direct Supply Agreements; Radiopharmaceutical Distributors; Hospital Procurement Channels; Research Supply Networks
• 3) By Application: Neuroendocrine Tumor Treatment; Prostate Cancer Treatment; Bone Metastasis Treatment; Clinical Research Applications; Other Applications
• 4) By End User: Hospitals; Specialty Cancer Clinics; Research Institutes; Radiopharmaceutical Companies; Diagnostic Centers
• Subsegments:
• 1) By Reactor Produced Lutetium One Hundred Seventy-Seven: Direct Neutron Activation Reactor Produced Lutetium One Hundred Seventy-Seven; Indirect Reactor Produced Lutetium One Hundred Seventy-Seven; High Purity Reactor Produced Lutetium One Hundred Seventy-Seven; Medical Grade Reactor Produced Lutetium One Hundred Seventy-Seven
• 2) By Cyclotron Produced Lutetium One Hundred Seventy-Seven: Proton Irradiation Cyclotron Produced Lutetium One Hundred Seventy-Seven; High Specific Activity Cyclotron Produced Lutetium One Hundred Seventy-Seven; Research Grade Cyclotron Produced Lutetium One Hundred Seventy-Seven; Commercial Scale Cyclotron Produced Lutetium One Hundred Seventy-Seven
• 3) By Carrier Added Lutetium One Hundred Seventy-Seven: High Activity Carrier Added Lutetium One Hundred Seventy-Seven; Reactor Derived Carrier Added Lutetium One Hundred Seventy-Seven; Clinical Grade Carrier Added Lutetium One Hundred Seventy-Seven; Industrial Use Carrier Added Lutetium One Hundred Seventy-Seven
• 4) By Non Carrier Added Lutetium One Hundred Seventy-Seven: High Specific Activity Non Carrier Added Lutetium One Hundred Seventy-Seven; Medical Grade Non Carrier Added Lutetium One Hundred Seventy-Seven; Therapeutic Use Non Carrier Added Lutetium One Hundred Seventy-Seven; Research And Diagnostic Non Carrier Added Lutetium One Hundred Seventy-Seven
• Companies Mentioned: Novartis AG; Telix Pharmaceuticals Limited; Bayer AG; Cardinal Health Inc.; Siemens Healthineers AG; Curium International Trading B.V.; Eckert & Ziegler SE; NRG PALLAS B.V.; State Atomic Energy Corporation Rosatom; Framatome SAS; BWX Technologies Inc.; National Centre for Nuclear Research Radioisotope Centre POLATOM; Isotopia Molecular Imaging Ltd.; Nusano Inc.; ITM Isotope Technologies Munich SE
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.